Form 4: Stoke Therapeutics Director Adrian Krainer Granted Stock Options Valued at $10.9 Per Share

Stoke Therapeutics, Inc. Director Adrian R. Krainer was granted 29,747 stock options with an exercise price of $10.9 per share, aligning his interests with shareholder value.

Summary

• Adrian R. Krainer, a Director of Stoke Therapeutics, Inc. (STOK), was granted 29,747 Director Stock Options.
• The transaction date for this grant was June 3, 2025.
• Each option has an exercise price of $10.9.
• The options are set to expire on June 2, 2035.
• The options will vest in full on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, contingent on Mr. Krainer's continued service to the company.
• Following this transaction, Mr. Krainer beneficially owns 29,747 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with the company's long-term performance, which is generally viewed favorably by investors. It is a routine compensation event, not indicative of significant operational changes.

Positives

• The grant of stock options to Director Adrian R. Krainer aligns his financial interests with the long-term performance and shareholder value of Stoke Therapeutics, Inc.
• The vesting schedule, tied to continued service, incentivizes the director's ongoing commitment to the company.

Future Outlook

The granted stock options are subject to future vesting, which will occur on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, provided the director continues his service to the company.

Industry Context

This Form 4 filing represents a routine insider transaction where a director receives equity compensation, a common practice in the biotechnology industry to attract and retain talent and align management interests with long-term company performance. Such grants are standard components of executive and board compensation packages.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which frequently use equity-based incentives to align board members' interests with shareholder returns.
• The vesting schedule tied to continued service is typical for director equity grants, ensuring commitment and long-term engagement, comparable to governance practices seen in many publicly traded life sciences companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align the director's interests with those of the shareholders, potentially leading to better long-term decision-making focused on increasing share value.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for equity incentives within the company.

Next Steps

• The granted stock options will vest on the earlier of June 3, 2026, or the date of Stoke Therapeutics' next annual meeting of stockholders, subject to Adrian R. Krainer's continued service.

Key Dates

Keywords

Stoke Therapeutics, STOK, Stock Option, Director Grant, Insider Transaction, SEC Form 4, Equity Compensation, Biotechnology